CDXS stock forecast, quote, news & analysis
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes... Show more
Codexis (CDXS) Stock Analysis: Building Enzymatic Capacity for the RNAi Boom
Key Takeaways
- CDXS shares have traded in a narrow low-single-digit range over the past 30 days, posting only a modest decline well below the 10% threshold that would signal a major price move.
- Codexis runs two complementary businesses: a stable small-molecule biocatalysis unit and the ECO Synthesis platform, an enzymatic route for manufacturing RNAi (siRNA) therapeutics.
- Management reaffirmed full-year 2026 revenue guidance of $72 million to $76 million and expects gross margins in the high-60% range.
- The company ended the second quarter of 2026 with $54.9 million in cash and short-term investments, enough to fund operations through the end of 2028.
- Near-term catalysts include a planned FDA meeting in the fourth quarter of 2026 and construction of its ECO GMP manufacturing facility, with full production targeted for late 2027.
- Investors can review additional details on Price Targets, Earnings, and Forecast to track the company's valuation and outlook.
- Explore Trending AI Robots for algorithmic trading strategies across thousands of tickers.
Current Market Snapshot
Codexis (CDXS) has been consolidating in the low-to-mid $1 range in recent weeks, reflecting a period of digestion following a broader decline from earlier highs. Over the trailing twelve months, the stock has traded in a wide range between roughly $0.96 and $3.87, underscoring the volatility typical of clinical-stage and platform biotech names. The current price level places the stock near the lower portion of that band, with the modest 30-day move suggesting investors are weighing the company's near-term execution against its longer-term opportunity in enzymatic RNA manufacturing.
Codexis (CDXS) Business Overview and Competitive Position
Codexis is an enzyme engineering company that uses its proprietary CodeEvolver technology platform to discover, develop, and enhance high-performance enzymes. The company operates across two primary areas. First, its small-molecule biocatalysis business supplies enzymes that improve the efficiency and economics of pharmaceutical manufacturing, with enzymes used in a portfolio of commercially approved drugs. Second, its ECO Synthesis platform aims to enable scalable, enzymatic manufacturing of RNA interference (RNAi) therapeutics, positioning the company at the intersection of synthetic biology and the rapidly growing field of siRNA-based medicines.
The company's competitive strengths include deep expertise in directed enzyme evolution, established relationships with major pharmaceutical and CDMO partners, and a differentiated enzymatic approach to oligonucleotide synthesis that management argues could address capacity and cost constraints in conventional solid-phase chemical synthesis. Investors follow CDXS closely because its growth story hinges on whether ECO Synthesis can industrialize and capture demand as RNA-based therapies expand beyond rare diseases into larger patient populations.
Recent Developments Driving CDXS
Several verified developments have shaped the stock's recent narrative. In the second quarter of 2026, Codexis reported total revenues of $14.9 million, slightly below the prior-year period, while narrowing its net loss to $12.0 million from $13.3 million. Management reaffirmed its 2026 revenue outlook of $72 million to $76 million and guided gross margins into the high-60% range, aided by higher-margin product mix.
The ECO Synthesis platform remains the central catalyst. Codexis has been advancing its enzymatic siRNA manufacturing capability, including work on stereochemical control and a "starterless" synthesis approach presented at industry conferences. The company has engaged with three contract development and manufacturing organizations (CDMOs), completed small-scale technology transfers, and continues toward a long-term commercial agreement with at least one partner. In January 2026, Codexis signed an evaluation agreement with Axolabs to expand the platform for oligonucleotide therapeutics.
On the manufacturing front, Codexis plans to submit a building permit application and begin retrofit construction of its ECO GMP manufacturing facility in the second half of 2026, targeting full production capability by the end of 2027 to supply siRNA material for preclinical and Phase 1 work. The company has also continued its engagement with the U.S. Food and Drug Administration's Emerging Technologies program, with an agency meeting anticipated in the fourth quarter of 2026.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of algorithmic trading strategies drawn from a much larger ecosystem of AI-driven bots. Tickeron offers hundreds of trading bots that operate across thousands of tickers, but only the top-performing and most relevant bots appear in this featured section. These bots vary widely in strategy, trading timeframe, and performance metrics, giving users a way to compare approaches rather than a single one-size-fits-all system. For traders seeking systematic, data-driven methods to complement their own research, the page provides a useful starting point to evaluate what is currently working in the market.
2026 Outlook and What Investors Should Watch
Looking ahead, Codexis' 2026 trajectory will likely be driven by execution on the ECO Synthesis platform. Key items to monitor include the company's ability to convert CDMO evaluations into long-term commercial agreements and whether it can begin an additional strategic partnership before year-end. The planned fourth-quarter 2026 FDA meeting and any progress toward an Advanced Manufacturing Technologies (AMT) designation could provide clarity on the regulatory path for enzymatic siRNA manufacturing.
Financial milestones also matter. Investors should watch whether product gross margins hold in the high-60% range and whether revenue tracks within the $72 million to $76 million guidance. Progress on the GMP facility buildout, continued scale-up toward kilogram-level production, and clinical data readouts across the biocatalysis pipeline represent additional catalysts. Risks include customer concentration, dependence on a limited number of contracts and milestones, competition from larger manufacturers, and the inherent uncertainty of commercializing a new manufacturing platform. As always, these factors should be weighed carefully rather than treated as a forecast of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
CDXS's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for CDXS moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 31 of the 34 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDXS advanced for three days, in 216 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CDXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CDXS as a result. In 79 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for CDXS turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 38 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CDXS entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.588) is normal, around the industry mean (3.498). P/E Ratio (-3.273) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.588) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. CDXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biocatalytic chemical processes
Industry Biotechnology